Clinical Study

Gog-3031- A Phase 3, Randomized, Double-Blind, Multicenter Study Of Dostarlimab (Tsr-042) Plus Carboplatin-Paclitaxel Versus Placebo Plus Carboplatin-Paclitaxel In Patients With Recurrent Or Primary Advanced Endometrial Cancer (Ruby)

Posted Date: Oct 26, 2020

  • Investigator: Caroline Billingsley
  • Specialties: Cancer, Gynecology, Oncology
  • Type of Study: Drug

The purpose of this study is to determine the rate of progression free survival in Dostarlimab plus Carboplatin-paclitaxel compared to carboplatin-paclitaxel plus a placebo in patients with Recurrent or Primary Advanced Endometrial Cancer


To Be Eligible: Histologically Or Cytologically Proven Endometrial Cancer With Recurrent Or Advanced Disease, Ecog 0-1, Adequate Organ Function, No Neo-Adjuvant/Adjuvant Systemic Chemotherapy For Primary Stage Iii Or Iv Disease, No Other Malignancy Within 3 Years, No Past Or Active Medical Disorder Or Infection That May Impact Safety On Treatment Or Impact Study Results


Endometrial Cancer, Uterine Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.